The Effect of an Intravitreal Dexamethasone Implant for Refractory Posterior Scleritis
10.3341/jkos.2021.62.3.322
- Author:
Seung Kwon CHOI
1
;
Youn A CHOI
;
So Hee KIM
;
Jae Jung LEE
;
Ik Soo BYON
;
Ji Eun LEE
;
Sung Who PARK
Author Information
1. Department of Ophthalmology, Pusan National University College of Medicine, Busan, Korea
- Publication Type:Original Article
- From:Journal of the Korean Ophthalmological Society
2021;62(3):322-328
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Purpose:To report the effect of an intravitreal dexamethasone implant on refractory posterior scleritis.
Methods:The medical records of patients treated with an intravitreal dexamethasone implant for non-infectious refractory posterior scleritis were retrospectively reviewed, including age, sex, duration of follow-up, and presence of associated systemic diseases. The duration until relapse, changes in visual acuity, number of implants, and side effects associated with the implant were also analyzed.
Results:Seven eyes from five patients were included. The mean age was 73.2 ± 12.5 years (59-92 years). Although all patients had been treated with high-dose systemic steroid, and immunosuppressants were added, the posterior scleritis was poorly controlled. The duration from the diagnosis to the first dexamethasone implant was a mean of 8.2 months (3-27 months). The scleritis was well controlled in all eyes until at least 2 months (2-5 months) after inserting the implant. An average of 2.1 (total of 15 times in the seven eyes) implants were inserted. No complications related to the implant were observed other than a temporary increase in intraocular pressure in one eye.
Conclusions:Intravitreal dexamethasone implants were an effective treatment option for refractory posterior scleritis.
